Abstract 1380P
Background
The lung cancer is the leading cause of death due to cancer in Western countries, the prognosis depends on the tumor stage and the clinical, histological and molecular characteristics.
Methods
The RTT study of the Spanish Lung Cancer Group is a database that includes the data of patients with lung malignant neoplasms. The objective of this retrospective study is to descriptive the clinical and epidemiological aspects of NSCLC in the Spanish population.
Results
The total of patients included in the RTT is 12.897 (Aug 2016 - Jan 2020) and this report is based in the analysis of 5.049 of them. The clinical and demographic data are described in the table. Adenocarcinoma (72,2%), squamous cell carcinoma (SCC) (18,6%), other types. The sites of metastasis: contralateral lung (34.3%), bone (31%), liver (12.8%) and CNS (6.02%). The first-line of treatment was chemotherapy (CT) in 66,54%, oral target therapy 13,45%, immunotherapy (IO) 8,62% and CT+IO 2,46%. The median of PFS of 7.4 months (7.13-7.6 months) in all population with an estimated at 6, 12, 24, and 60 months of 58.3% (95%CI 56.81% - 59.74%), 29.97% (95%CI 28.56% - 31.4%), 13.4% (95%CI 12.2% - 14.6%) and 2.6% (95%CI 1.98%-3.5%) respectively. The median of OS was 15.5 months (14.8-16.4). According to the histological type (SCC vs non-SCC), the median (in months) of PFS was 6.67 (6.1- 7.1) vs 7.53 (7.3-7.9) (HR 0.78, 95% CI 0.72 - 0.85) and OS 13.8 (12.6-15.6) vs 16.9 (15.7 - 18) in non-SSC, p <0.001. The analysis of survival in patients with or without liver metastasis showed a median OS of 15 months (14.3-16m) vs 18.1 months (16.1- 19.9m), HR 0.88, 95%CI 0.79-0.98 (p<0.05). Table: 1380P
| N=5049 | |
| Age, Median | 68, 29 y (25-96) |
| Sex | M:71,16% - F:28,83% |
| Smoking habit Smoker Former smoker Never smoker | 42,42% 41,06% 15,56% |
| Asbestos exposure | 2,14% |
| Patient history of cancer | 13,5% |
| Family history of cancer | 40,82% |
Conclusions
The results of our study show a similarity in the clinical characteristics of patients with NSCLC in the Spanish population with the data in the western population previously described. Both, the histological subtype and the presence of liver metastases are predictive factors for survival.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Fundacion GECP.
Funding
AstraZeneca, Novartis, Roche.
Disclosure
All authors have declared no conflicts of interest.